Clinical Trial Update: Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease

View source ↗

Summary

A clinical trial evaluating JAK inhibitors for systemic sclerosis–associated interstitial lung disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Interstitial Lung Disease

Snippet

Sponsor: Central Hospital, Nancy, France | Conditions: Systemic Sclerosis, Interstitial Lung Disease | Status: WITHDRAWN